A double-blind parallel comparison of iopamidol and metrizamide for myelography was performed in 36 patients. Sixteen adverse reactions were noted in 10 patients who received metrizamide. Six adverse reactions were reported in five patients who received iopamidol. There was no appreciable difference in the radiographic opacification.
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Clinical Comparison of Metrizamide and lopamidol for yelography
Patrick A. Turski,1 Joseph F. Sackett, Lindell R. Gentry , Charles M. Strother, and Francesco Matozzi A double-blind parallel comparison of iopamidol and metrizamide for myelography was performed in 36 patients. Sixteen adverse reactions were noted in 10 patients who received metrizamide. Six adverse reactions were reported in five patients who received iopamidol. There was no appreciable difference in the radiographic opacification.
The development of non ionic water-soluble contrast media for myelography has resulted in improved anato mi c delin eati on and better patient toleran ce [1 , 2] . Metri za mid e was the first mye lographic contrast medium th at fulfill ed th e need for a contrast malerial of low neurotoxicity and suffic ient radiopacity whil e being miscible with cerebrospinal fluid (CSF). Neverthele ss, adverse reactions related to the toxic ity of th e contrast material oc cur after metrizamide myelography [2] [3] [4] [5] [6] . Consequently, a new contrast medium , iopamidol (Bracco , Milan, Italy; and Squibb , Prin ceton, NJ), has been developed in th e hope of fin d ing an even less toxic material. In this investigation iopamidol was compared w ith metrizamide to assess rel ative toxic ity and radiographic opacificati on following intrathecal injection.
Materials and Methods
The study was perform ed as a doubl e-blind parallel compari son in whi ch each patient was rando ml y assigned either iopamidol or metrizamid e. The contrast material was dispensed by a member of the neuroradiology service outside th e myelographi c room. Th e foll owin g conditions exclud ed patients fro m th e study: under 18 yea rs of age; women of c hildbearin g potential not using an effecti ve contraceptive; pregnancy; surgery required within 24 hr of th e rad iologic examination; hypersensitivity to any form of contrast agent; spinal puncture within the last month ; frankly blood y CSF obtain ed after lumbar puncture; increased intracranial pressure or suspicion of intracranial tumor, ab scess, or hematoma ; treatm ent with phenothiazine derivitives, butyrophenones , tricyc li c antidepressants, monoamine o xidase inhibitors, or analeptics within 1 week of the study; history of convulsive disorder or multiple sclerosis; history of psychosis; history of al c holism or drug abuse. Thirty-s ix patients were studied , 18 with iopamidol and 18 with metrizamide. Eight cervi cal, si x th oracic, 20 lumbar, and two complete myelograms were obtained , equally divided between iopamidol and metrizamide .
Clinical Observa tions
Th e patients we re evalu ated be fore mye log raphy with hi story, ph YS ica l examin ati on, and neurolog ic examinati on by a member of th e neurology departm ent. Vit al signs (pul se, respiratory rate, temperature, and supine blood press ure) we re recorded be fore and at 15 min, 30 min, 1 hr, 4 hr, and 24 hr aft er th e injec tion of the contrast materi al.
Laboratory Profiles
Hematologic survey, c hemi stry survey, and urin alys is were perform ed before mye lograph y and at 24 and 72 hr after th e proced ure. CSF obtain ed during th e myelogram was sent for ce ll count , total protein , glucose, and c hl ori de .
Th e pati ents received a c lear li q uid breakfast before mye log raphy and were not premedi cated . Fluid s we re encouraged after myelography to in sure adequate hydrati on.
Th e co ntrast materi al was administered th ro ugh a 22 gauge needle, whic h was pl aced at th e L2-L3 interspace for th e lum bar and th oracic examinati ons. After lumbar puncture 3 -5 ml of CSF was removed and 10 -1 5 ml of 200 mg Il m l contrast materi al was introduced (m etrizami de reconstituted with 13.2 ml of diluent). Cervical examinati ons were perform ed via a lateral C1-C2 pun cture and 8-15 ml of contrast materi al (300 mg I/ ml ) was injec ted , depending on th e volum e of th e cervi cal canal.
Foll owin g th e procedure pati ents remained passive in bed with heads elevated 30° for 8 hr. Foll owin g thi s, th e pati ent s were allowed to have bathroom privileges and li e in th e horizontal position.
Anteroposteri or and obli que film s were obtain ed w ith both horizo ntal and ve rti cal beam techniques. Th e film s we re evalu ated for technica l quality and radiog raphi c opac ificati on by a neu roradiologist (J . F. S.), wh o d id not know whi c h contrast mate rial had been ad mini stered . Film s th at were technicall y adequate we re g raded as: 0 , no visualizati on or opacificati on; 1 , poor visuali zati on or fai nt opacification, in adequate for d iag nosis; 2 , adeq uate for visuali zati on or suffic ient opac ificati on for diag nosis; or 3 , superi or visualizati on or opacificati on permittin g diag nosi s easil y.
Th e patients underwe nt repeat neuro logic examinati on and laboratory stud ies 24 hr aft er mye log raph y. Adverse reac ti ons were recorded in c lu din g th e tim e of onse t, duration, and severity . Reacti ons we re consid ered mil d w hen they d isappeared spontaneously without treatm ent. Moderate reactions were defined as those ne- cessitating treatm ent but responding immediately to such treatment. Severe reacti ons were defin ed as alarming or li fe-threaten ing reactions th at responded poorly or slowly to treatment or did not respond to treatment. 8 (4) 4 (4) 3 (3) 10 (10) 1 (1) . Required analgesics but respond ed quickly.
A B Fig . 1 . -Cervical iopamidol myelogram via C1-C2 puncture (1 0 ml of 300 mg I/ ml). Anteroposterior (A) and lateral (B) views clearly demonstrate cervical subarachnoid space. Ventral and left latera l extradural lesio ns at C3-C4 and C4-C5.
Results
The adverse reactions are summarized in table 1. The procedure was well tolerated by both groups. Sixtee n adverse reactions were noted in 10 patients who received metrizamide . Si x adverse reactions were repo rted in five patients who received iopamidol. There were no serious adverse reactions to either contrast material. Eight patients reported headache after metrizamide myelography; two J f them required analgesics. Three patients reported headache after myelography with iopam idol; none of them required analgesics. Tre two groups could be statistically differentiated w ith p < 0 .1.
Th e radiographic opacification was adequate for diag noSis in :tl i patients . The opacity was considered superior in 10 patients who received iopamidol (fig s. 1-3 ) and in nine patients who rece ived metrizamide. There were no abnormalities of the laboratory investigation s related to th e contrast materials, and the vital signs di d not fluctuate appreciably in relation to myelography .
Discussio n lopamidol is a non ionic compound composed of a triiodin atl'd benzen e ring with three high ly hydrophilic side chains ( fig . 4 ). It h l S a molecular weight of 777 and an iod ine content of 49% . At a concentration of 300 mg I/ ml the osmolality is 0 .616 mol / kg and the viscosity at 37"C is 4 . In a double-blind study of 200 patients undergoing lumbar myelography, Hammer and Lackner [7] did not detect any difference in the incidence or severity of adverse reactions between iopamidol and metrizamide. However, Drayer et al. [8] noted that the striking features of the 12 patients in their series (lumbar iopamidol myelography) were the mildness of the reactions and the excellent patient tolerance of the procedures. Similarly , Belloni et al. [9] co nsidered the most significant aspect of th eir study with iopamidol for cerv ical myelography in 65 patients to be the complete absence of neurologic symptoms other than headache.
In ou r limited experience adverse reac ti ons occurred less often in th e group of patients who received iopamidol. The side effec ts associated with iopamidol we re generally mil d and of short er durati on th an those of th e metrizamide group. Of particular note, there were no alteration s in consc iousn ess or seizure ac ti vity in any of the patients receiv ing iopamidol.
Th e potential of iopamidol for producing arac hnoiditis has been investig ated in macaque monkeys. The preliminary results indicate iopam idol is eq ui valent to metrizamide with respect to th e risk of arac hn oiditis [10] .
lopamidol is absorbed from th e subarac hn oid space sli ghtly faster than metrizamide [7] . It enters th e intrac rani al subarac hnoid spaces following th e normal pathways of CSF resorption. Electroencephalography after lumbar myelography revealed three or four bursts of diffuse intermittent delta activity with no epil eptiform spikin g [8] . Th e exact epil eptogeni c potential o f iopamidol has not been c learl y defined in man.
In this investig ati on only 18 patients were studied with each co ntrast materi al and it is th erefore not possible to draw any firm conc lusion s regarding th e relative toxic ity . However, iopamidol produced fewer adverse reacti ons than metri zam ide and th ose that were encountered were mild in nature. lopamidol has the add itional advantages of being stable in soluti on and having a long shelf life .
